Ultragenyx Pharmaceutical

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Ultragenyx Pharmaceutical 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About RARE

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. 

CEO
Emil D. Kakkis
CEOEmil D. Kakkis
Employees
1,294
Employees1,294
Headquarters
Novato, California
HeadquartersNovato, California
Founded
2010
Founded2010
Employees
1,294
Employees1,294

RARE Key Statistics

Market cap
2.39B
Market cap2.39B
Price-Earnings ratio
-4.05
Price-Earnings ratio-4.05
Dividend yield
Dividend yield
Average volume
2.40M
Average volume2.40M
High today
$24.91
High today$24.91
Low today
$23.56
Low today$23.56
Open price
$23.79
Open price$23.79
Volume
3.43M
Volume3.43M
52 Week high
$46.50
52 Week high$46.50
52 Week low
$18.41
52 Week low$18.41

Stock Snapshot

As of today, Ultragenyx Pharmaceutical(RARE) shares are valued at $24.66. The company's market cap stands at 2.39B, with a P/E ratio of -4.05.

On 2026-02-02, Ultragenyx Pharmaceutical(RARE) stock traded between a low of $23.56 and a high of $24.91. Shares are currently priced at $24.66, which is +4.7% above the low and -1.0% below the high.

Ultragenyx Pharmaceutical(RARE) shares are trading with a volume of 3.43M, against a daily average of 2.4M.

During the past year, Ultragenyx Pharmaceutical(RARE) stock moved between $18.41 at its lowest and $46.50 at its peak.

During the past year, Ultragenyx Pharmaceutical(RARE) stock moved between $18.41 at its lowest and $46.50 at its peak.

RARE News

Simply Wall St 1d
Ultragenyx BLA Resubmission Puts UX111 And RARE Valuation In Focus

Ultragenyx Pharmaceutical resubmitted its Biologics License Application to the FDA for UX111, a gene therapy candidate for Sanfilippo syndrome type A. The fili...

Ultragenyx BLA Resubmission Puts UX111 And RARE Valuation In Focus
TipRanks 3d
Ultragenyx Resubmits UX111 Gene Therapy for FDA Review

Ultragenyx Pharmaceutical ( (RARE) ) has issued an update. On January 30, 2026, Ultragenyx Pharmaceutical resubmitted its Biologics License Application to the...

Analyst ratings

95%

of 22 ratings
Buy
95.5%
Hold
4.5%
Sell
0%

People also own

Based on the portfolios of people who own RARE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.